Company

WHO WE ARE

PLUS THERAPEUTICS is a clinical-stage pharmaceutical company focused on making a positive impact on patients' lives and adding value to the healthcare system. We are a publicly traded company on Nasdaq (PTCT), an abbreviation of POSITIVE! (with our headquarters in Austin, Texas and GMP validated manufacturing facilities in Austin, Texas and Frederick, Colorado. We have a proven track record of successfully developing and manufacturing complex pharmaceutical products, including nanomedicines and the ability to quickly and rapidly file funding through the Cancer Prevention and Research Institute of Texas, as CPRIT. Since being founded in 2004, CPRIT has awarded almost $2.5 billion to fund research more than 1,500 grants for cancer prevention and academic/product development research.

We have two lead drug product candidates in our pipeline: RNL-Doxo-DUO™ and DoseSafe™, being developed in the U.S. by a dedicated and energetic team of biologists, chemists, engineers, physicians, and other professionals. This diverse and experienced team is using our proprietary and versatile nanotechnology platform to reformulate and deliver U.S. FDA-approved chemotherapeutics and radiopharmaceuticals in new ways to provide meaningful benefits to patients and healthcare providers. The platform also serves as the foundation and efforts as the opportunity in the future to develop additional drugs for rare cancers.

OUR MISSION

We believe in the critical importance of discovering, developing, and delivering complex and innovative treatments for patients battling rare cancers.

OUR VISION

We envision medicines that will drastically enhance clinical and economic outcomes for patients and providers and forever change the future of human health worldwide.

OUR VALUES

Our company values guide our beliefs, behaviors, and interactions.
Our goal is to live out these values everyday, everywhere, and with everyone.

Accountability
Reliability, responsibility, and taking ownership of our work.

Agility
Ability to quickly respond and adapt to internal and external changes without losing our momentum.

Communication
Fostering transparency and direct feedback from colleagues, partners, providers, and patients alike.

Innovation
Encouraging curiosity and courage to boldly experiment and discover.

Integrity
Consistently remain ethical and commit to doing what's right, every time, no matter what.

Patient-Centric
Keep our purpose for the patient forever at the forefront of all we do.

Quality
Promise to deliver exceptional results and continually strive to enhance our standards.

Performance
Focus on achievement, taking smart risks, and delivering exceptional results.

Respect
Treat everyone we come in contact with dignity and kindness.

Teamwork
Cultivate a culture that encourages collaboration and welcomes different perspectives.

OUR MODEL

1. Landscape Mapping — Understand clinical & commercial opportunities • Define technology options
2. Redesign — Redesign the API with new technology
3. Reformulate & Manufacture — Manufacture reformulated drug • Non-clinical analysis
4. Clinical Utility — Prove safety • Define efficacy over standard of care
5. Partner & Commercialize — Partner for late stage clinical & regulatory approval • Commercial launch

MANAGEMENT TEAM

Marc Hedrick, MD
Chief Executive Officer

Dr. Marc Hedrick is the President and CEO at PLUS THERAPEUTICS, Inc. Previously, Dr. Hedrick served in a number of executive leadership roles including President, CEO and Director at Cytori Therapeutics, Inc., and President and CEO at StemSource, Inc. Dr. Hedrick is a trained general, vascular, and plastic surgeon. Additionally, Dr. Hedrick was a Professor of Surgery at the University of California, San Diego (UCSD) and Director of the Laboratory of Regenerative Bioengineering and Repair at UCLA. Dr. Hedrick obtained his MD from the University of Texas Southwestern Medical School, Dallas and a MBA from The Anderson School at UCLA in 2005.

Email

Andrew Sims
Executive Vice President and Chief Financial Officer

Andrew Sims is Vice President and Chief Financial Officer at PLUS THERAPEUTICS, Inc. Mr. Sims arrives at Plus Therapeutics having previously held Chief Financial Officer roles at several private equity-backed companies. His focus has been on mergers and acquisitions, investigations, corporate capitalization, and building out and managing teams to support global growth. Previously, Mr. Sims was Partner at Weaver, a global accounting, advisory, audit, tax and consulting firm. Mr. Sims is a graduate of the University of Texas at Austin with a BBA in Accounting and a MPA in Taxation. He is also a holding a variety of healthcare companies, with average annual revenues in excess of $1 billion. Further, he has been a partner on over 50 acquisitions ranging from $5 million to $4 billion in purchase price. Mr. Sims is a native of the United Kingdom and is now a proud U.S. citizen. He is a Certified Public Accountant in the U.S. and a Chartered Accountant in England and Wales. He is a graduate of Buckingham University in the United Kingdom.

Email

Russ Havranek
Vice President, Corporate Strategy and New Product Planning

Russ Havranek is the Vice President of Corporate Strategy and New Product Planning at PLUS THERAPEUTICS, Inc. He was previously Vice President of Global Marketing and Business Development at Cytori Therapeutics Inc. Mr. Havranek has 24 years of pharmaceutical experience in marketing, business development, and sales. He has held senior positions at companies including Johnson & Johnson, Guidant Corporation (now Abbott), Genentech, and Baxter Healthcare and Volcano Corporation (now Philips). Mr. Havranek received a MBA in Marketing from the Haas School of Business at the University of California, Berkeley, a MS in Bioengineering from Clemson University, and a BS in Biomedical Engineering from Northwestern University.

Email

Cheri Rice
Vice President - Product Development

Cheri Rice is the Vice President of Product Development at PLUS THERAPEUTICS, Inc. She previously served in the same role at Cytori Therapeutics, Inc. Prior to that, Ms. Rice was Director of Product Development at Volcano Corporation, a leading developer of intravascular ultrasound diagnostic equipment from June 2000 until May 2015. Prior to Volcano she worked her way up through the ranks at Abbott Vascular, ending her tenure as Manager of Process Development. She brings 25 years of Program Management and Engineering experience to Plus Therapeutics. Ms. Rice has her bachelor's degree in Mechanical Engineering from San Diego State University.

Email

Gregory Stein, MD
Senior Vice President - Clinical Development

Dr. Gregory Stein is Senior Vice President of Clinical Development at PLUS THERAPEUTICS, Inc. Prior to joining PLUS, Dr. Stein was a founder and executive of a number of healthcare and biotechnology companies. Most recently he co-founded Cellmid Limited, a biotechnology company developing novel therapeutics for cancer and infectious diseases, and served as director and other board-level roles. Cellmid was awarded funding from the Cancer Prevention and Research Institute of Texas. Prior to Cellmid, Dr. Stein was also a founder and served as the Vice President, Operations and Medical Affairs at Sosa Pharmaceuticals, a specialty pharmaceutical company developing novel therapeutics for cancer and other serious diseases. Sosa was acquired by Genepharm, a European pharmaceutical company. Dr. Stein has also held senior positions at Genepharm, Sosa Pharmaceuticals and Gentronix Biosciences.

Dr. Stein was formerly a board certified Emergency Medicine Physician and previously practiced in Chicago serving as the Assistant Medical Director of the department and Associate Emergency Medical Services Director for the regional EMS system.

Dr. Stein is a graduate of the accelerated program at the Ohio State University School of Medicine and completed his residency at the University of Illinois Affiliated Hospitals in Chicago. In addition, Dr. Stein has a MBA from The Rady School of Management at UC San Diego.

Email

Kara Davis
Corporate Counsel

Email

BOARD OF DIRECTORS

Richard Hawkins
Director

Richard J. Hawkins joined us as Director in December 2007 and was appointed to serve as Chairman in January 2019. Mr. Hawkins is currently the CEO of Luminia Pharma, Inc., a start-up pharma company. Mr. Hawkins founded LadRx Inc., a biotech company developing novel therapeutics for cancer, in 2013 and served as its Chairman and Chief Executive Officer until its Chairman and CEO from 2013 until 2018. Mr. Hawkins previously founded and guided the growth of Pharmacia, a clinical drug development services company where he served as Chairman, President, and Chief Executive Officer. He is a director of Cytokinetics, Incorporated, a publicly traded biotechnology company, and Ligand, Inc., a publicly traded biotechnology company that was sold to Pfizer, and Cosmos Biotechnology Services, and served as Chairman of the Board for LoopCine, Inc., a shopping and logistics software company. Mr. Hawkins holds a B.S. in biology from Ohio University.

Marc Hedrick, MD
Founding Director

Dr. Marc Hedrick is the President and CEO at PLUS THERAPEUTICS, Inc. Previously, Dr. Hedrick served in a number of executive leadership roles including President, CEO and Director at Cytori Therapeutics, Inc., and President and CEO at StemSource, Inc. Dr. Hedrick is a trained general, vascular, and plastic surgeon and additionally was Professor of Surgery and Pediatrics at the University of California, Los Angeles (UCLA). Dr. Hedrick also served as Co-Director of the Laboratory of Regenerative Bioengineering and Repair at UCLA. Dr. Hedrick obtained his MD from the University of Texas Southwestern Medical School, Dallas and a MBA from The Anderson School at UCLA in 2005.

Email

An van Es-Johansson, MD
Director

An van Es-Johansson joined our Board in January 2020. Dr. van Es-Johansson currently serves as the Chief Medical Officer for AcuraCure Pharma, a Swedish pharmaceutical company with a primary focus on Alzheimer's disease, where she is responsible for the clinical development and medical affairs of pharmaceutical products. Prior to this, Dr. van Es-Johansson served in a range of executive roles of increasing responsibility at leading pharmaceutical companies Bristol-Myers Squibb, an international specialty biopharmaceutical company focused on cancer therapies. Dr. van Es-Johansson has leadership experience within large pharmaceutical and smaller biotechnology companies, including Roche, Eli Lilly, Active Biotech, and Bioservo. She currently serves on the Board of Directors at Bioservo International AB, Mentor AB, Agendia Inc., and Saxura, Inc. Dr. van Es-Johansson received a M.D. from Erasmus University in Rotterdam, The Netherlands.

Greg Petersen
Director

Greg Petersen has served on our Board since February 2020. Mr. Petersen is an accomplished Executive and Board Director with more than 25 years of experience operations, finance and commercial leadership experience. He is Chairman of the Board of Directors of Medtronic Inc., a medical device company and is a member of the Audit Committee. He is a member of PEAKS Holdings and as Audit Committee Chair of Windsor Group Holdings. Mr. Petersen has served as Executive Chairman of Diligent Corporation and as Chief Financial Officer of Command Software and Actuate Software Solutions (now part of Opentext). He has also held executive positions at American Airlines and other corporations. Mr. Petersen has a BS from Boston College and an MBA from Duke University's Fuqua School of Business.

Robert Leck, PhD
Director

Robert Leck joined our Board in March 2020. Dr. Leck has over 35 years as pharmaceutical executive with deep expertise in nanoparticle drug development and drug formulation. He is currently President of Lenk Pharmaceuticals, a pharmaceutical consulting company he founded in 2016 to provide drug development services. Prior to that he was Chief Scientific Officer of BioMimetix, Inc., developer of the NanoMatrix division of Luna Innovations, Inc., President & CEO of Therapeutics 2020, Inc. and Vice President of Research & Development at Argus Pharmaceuticals. Dr. Leck was also Cofounder of The Liposome Co. and a staff Fellow of the National Institutes of Health in Clinical Investigation and Development. He has a PhD and BS from the Massachusetts Institute of Technology and resides in Danville, Virginia.

Howard Clowes
Director

Howard Clowes joined our Board in March 2020. A retired partner after nearly four decades at EY& Peter, a leading law firm, Mr. Clowes has served in leadership positions in the firm's Corporate and Securities Practice, advising public and private companies on securities law, financing, mergers and acquisition and general corporate matters. At the law firm of Foley & Lardner LLP, Mr. Clowes served as Chairman of the Board of Directors and as a member of the Executive Committee and managing partner of the Transactions Group. Mr. Clowes has a J.D. from the University of California, Berkeley (where he now serves as a Lecturer), and a BA from the University of California, Santa Barbara. A resident of the Bay Area, Mr. Clowes serves on the Finance, Board Member and Chair of the Strategic Planning and Event Committees of the Law Foundation of Silicon Valley.

CLINICAL ADVISORY BOARD

Manish Aghi, MD PhD
Professor, Department of Surgery at the Weill Institute for Neurosciences at the University of California, San Francisco

Dr. Manish Aghi is a neurosurgeon, scientist and current faculty member in the department of neurological surgery and graduate division of biomedical sciences, as well as a principal investigator in the Brain Tumor Research Center at UCSF. He completed his MD-PhD Program through the Medical Scientist Training Program at Harvard Medical School, followed by neurological surgery residency and postdoctoral training at Massachusetts General Hospital. He is a principal investigator on multiple industry-sponsored and investigator-initiated Phase 1-2 clinical trials comparing neurosurgery versus anti-angiogenic therapy of recurrent glioblastoma, as well as investigating convection-enhanced delivery of multiple viruses and nanopharmaceutical therapeutics by recurrent glioblastoma.

Nicholas Butowski, MD
Professor in Residence, Vice Chair and Director, Translational Research, Neuro-Oncology at the Weill Institute for Neurosciences at the University of California, San Francisco

Dr. Butowski is a neuro-oncologist who specializes in brain tumors, neurocognitive, cognitive and rehabilitative neurology, and complementary therapies for neurological disorders. He is director of clinical services in neuro-oncology and co-investigator of National Cancer Institute-supported North American Brain Tumor Consortium clinical trials. Dr. Butowski earned his medical degree at the University of Illinois at Chicago and completed a residency in neurology and a fellowship in neuro-oncology at UCSF. He is a member of the American Academy of Neurology, American Society of Clinical Oncology and Society for Neuro-oncology.

Russell Lonser, MD
Professor and Chair, Department of Neurological Surgery at The Ohio State University Wexner Medical Center

Dr. Lonser is a professor and chair of the Department of Neurological Surgery at The Ohio State University Wexner Medical Center, and currently holds the Zaninger Family Chair in Neurosurgical Oncology. Previously, he was chief of the Surgical Neurology Branch at the National Institutes of Health. Dr. Lonser specializes in the resection of brain, spinal cord, pituitary and brainstem tumors. He is a director of the American Association of Neurological Surgeons, and was the head of the research committee for the Congress of Neurological Surgeons. He is a Fellow of the American College of Surgeons and the American Academy of Neurological Surgeons. Dr. Lonser has served on the editorial boards of NEUROSURGERY, World Neurosurgery, Journal of Neurosurgery, Pluck One and Science Reports.

Alireza Mohammadi, MD
Assistant Professor, Department of Neurological Surgery at The Ohio State University Wexner Medical Center

Dr. Mohammadi is a board-certified neurosurgeon who specializes in neurological oncology including surgery and laser ablation of brain tumors as well as radiosurgery for brain and spine. He is currently practicing at Neurosurgery Department and the Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center at the Cleveland Clinic Since 2016. Dr. Mohammadi has also served as an assistant professor in Neurological Surgery at the Cleveland Clinic Lerner College of Medicine. Dr. Mohammadi received his medical degree from Tehran University of Medical Sciences, Iran. After completing his residency in neurosurgery at Montefiore Medical Hospital, he went on to complete his fellowship in neuro-oncology surgery and his fellowships in radiosurgery at the Cleveland Clinic.

Michael Vogelbaum, MD PhD
Chair of Neurosurgery and Program Leader of the Department of Neuro-Oncology at Moffitt Cancer Center

Dr. Vogelbaum is an internationally known leader in neurological oncology and translational investigator in laboratory research, translational and clinical trials in gliomas. He is currently Chair of Neurosurgery and Program Leader of the Department of Neuro-Oncology at Moffitt Cancer Center. Dr. Vogelbaum is also a professor of Neurosurgery and Oncologic Sciences at the University of South Florida. He received his MD and PhD degrees from Case Western Reserve University School of Medicine and Brain and Drug Administration clearance. After completing his M.D. and Ph.D. (Biomedical Engineering) at the University of Virginia, Dr. Vogelbaum completed his residency in neurological surgery at Barnes-Jewish Hospital in St. Louis, Mo.

BUILT TO PERFORM

Powered by People, Equipment, Facilities, Suppliers

We have a GMP validated manufacturing facility and a warehousing facility located in San Antonio, Texas, USA. The facility and processes are designed to help comply with GMP as FDA and EMA regulations for manufacturing drug candidates for research, development, clinical, and commercial use. Upon approval of our drug product candidates, our manufacturing capabilities will include validated manufacturing processes for drug product as well as a quality assurance product release process with the ability to ultimately scale up the process to meet increasing market demand. We believe our strategic investments in the analytical and manufacturing capabilities, including personnel from drug discovery through drug development, will allow us to advance our product candidates more rapidly.

Expertise gained in manufacturing RNL™ DoxoPLUS™ and DoseSafe™ will be leveraged to support the manufacturing of other drug candidates as we further leverage our capabilities. Our San Antonio facility is also capable of producing a variety of other injectable sterile materials that may be of interest to other companies. Additionally, we have an internal Manufacturing Organization that has the ability to perform various manufacturing processes as we deem appropriate to meet our operational objectives.

Our current principal suppliers for our business are LGM Pharma and SinoPharm Taiwan, which supply our active pharmaceutical ingredients, or API, doxorubicin and docetaxel, respectively, as well as Lipoid, LLC and Dishman Netherlands, which supply us with certain other raw materials used in the manufacture of our DoxoPLUS™ and DoxoPLUS™ drug candidates, and Eurofins, Columbia who supplies testing support for all products.

CAREERS

Why Join Us?
At PLUS THERAPEUTICS our employees are dedicated to developing and delivering innovative nanomedicines to health care providers and their patients. Because we believe that each employee contributes directly to our growth and success, we strive to encourage both their professional and personal development.

We foster a work place culture in which our employees are respected and valued for their contributions and reward the team that makes for our innovative, fast-paced, and exciting business.

We are an equal opportunity employer dedicated to diversity and fairness in the work place and invite you to submit your resume.

Opportunities
There are no job openings at the time.

Benefits
PLUS THERAPEUTICS strives to provide its team with a comprehensive, competitive, and flexible selection of benefits to build health, wealth, and quality of life.

- Vacation (Paid Time Off - PTO)
- Health
- Life Protection
- Retirement Planning
- Employee Assistance

HEADQUARTERS
4200 Marathon Blvd.
Suite 200
Austin, TX 78756 USA
Tel: +1.737.255.7194
Fax: +1.866.456.6595

GENERAL INFORMATION
info@plustherapeutics.com

BUSINESS DEVELOPMENT
bd@plustherapeutics.com

HUMAN RESOURCES
hr@plustherapeutics.com

INVESTOR/PUBLIC RELATIONS
ir@plustherapeutics.com

Copyright © 2020 Plus Therapeutics, Inc. All rights reserved. Plus Therapeutics, RNL, DoxoPLUS, DoseSafe, and INSPECT are trademarks of Plus Therapeutics, Inc.